Literature DB >> 28778924

Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.

Kathryn E Tiller1, Lijuan Li1, Sandeep Kumar2, Mark C Julian1, Shekhar Garde1, Peter M Tessier3.   

Abstract

Antibodies commonly accumulate charged mutations in their complementarity-determining regions (CDRs) during affinity maturation to enhance electrostatic interactions. However, charged mutations can mediate non-specific interactions, and it is unclear to what extent CDRs can accumulate charged residues to increase antibody affinity without compromising specificity. This is especially concerning for positively charged CDR mutations that are linked to antibody polyspecificity. To better understand antibody affinity/specificity trade-offs, we have selected single-chain antibody fragments specific for the negatively charged and hydrophobic Alzheimer's amyloid β peptide using weak and stringent selections for antibody specificity. Antibody variants isolated using weak selections for specificity were enriched in arginine CDR mutations and displayed low specificity. Alanine-scanning mutagenesis revealed that the affinities of these antibodies were strongly dependent on their arginine mutations. Antibody variants isolated using stringent selections for specificity were also enriched in arginine CDR mutations, but these antibodies possessed significant improvements in specificity. Importantly, the affinities of the most specific antibodies were much less dependent on their arginine mutations, suggesting that over-reliance on arginine for affinity leads to reduced specificity. Structural modeling and molecular simulations reveal unique hydrophobic environments near the arginine CDR mutations. The more specific antibodies contained arginine mutations in the most hydrophobic portions of the CDRs, whereas the less specific antibodies contained arginine mutations in more hydrophilic regions. These findings demonstrate that arginine mutations in antibody CDRs display context-dependent impacts on specificity and that affinity/specificity trade-offs are governed by the relative contribution of arginine CDR residues to the overall antibody affinity.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; affinity maturation; amyloid-β (AB); antibody engineering; complementarity determining regions; directed evolution; monoclonal antibody; polyspecificity; protein stability; yeast surface display

Mesh:

Substances:

Year:  2017        PMID: 28778924      PMCID: PMC5633126          DOI: 10.1074/jbc.M117.783837

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Dissecting protein-protein recognition sites.

Authors:  Pinak Chakrabarti; Joël Janin
Journal:  Proteins       Date:  2002-05-15

2.  Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling.

Authors:  Benjamin J Hackel; Atul Kapila; K Dane Wittrup
Journal:  J Mol Biol       Date:  2008-06-24       Impact factor: 5.469

3.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site.

Authors:  C F Barbas; L R Languino; J W Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 4.  Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display.

Authors:  Benjamin J Tillotson; Yong Ku Cho; Eric V Shusta
Journal:  Methods       Date:  2012-03-23       Impact factor: 3.608

5.  A de novo protein binding pair by computational design and directed evolution.

Authors:  John Karanicolas; Jacob E Corn; Irwin Chen; Lukasz A Joachimiak; Orly Dym; Sun H Peck; Shira Albeck; Tamar Unger; Wenxin Hu; Gaohua Liu; Scott Delbecq; Gaetano T Montelione; Clint P Spiegel; David R Liu; David Baker
Journal:  Mol Cell       Date:  2011-03-31       Impact factor: 17.970

6.  Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  Anastasia Lambrianides; Ian Giles; Yiannis Ioannou; Lesley Mason; David S Latchman; Jessica J Manson; David A Isenberg; Anisur Rahman
Journal:  Arthritis Rheum       Date:  2007-07

7.  Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures.

Authors:  Michael Zemlin; Martin Klinger; Jason Link; Cosima Zemlin; Karl Bauer; Jeffrey A Engler; Harry W Schroeder; Perry M Kirkham
Journal:  J Mol Biol       Date:  2003-12-05       Impact factor: 5.469

8.  Large-scale analysis of somatic hypermutations in antibodies reveals which structural regions, positions and amino acids are modified to improve affinity.

Authors:  Anat Burkovitz; Inbal Sela-Culang; Yanay Ofran
Journal:  FEBS J       Date:  2013-11-26       Impact factor: 5.542

9.  Beyond natural antibodies: the power of in vitro display technologies.

Authors:  Andrew R M Bradbury; Sachdev Sidhu; Stefan Dübel; John McCafferty
Journal:  Nat Biotechnol       Date:  2011-03       Impact factor: 54.908

10.  Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key.

Authors:  Utpal Das; Gururao Hariprasad; Abdul S Ethayathulla; Pallavi Manral; Taposh K Das; Santosh Pasha; Anita Mann; Munia Ganguli; Amit K Verma; Rajiv Bhat; Sanjeev Kumar Chandrayan; Shubbir Ahmed; Sujata Sharma; Punit Kaur; Tej P Singh; Alagiri Srinivasan
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

View more
  17 in total

1.  Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity.

Authors:  Yulei Zhang; Lina Wu; Priyanka Gupta; Alec A Desai; Matthew D Smith; Lilia A Rabia; Seth D Ludwig; Peter M Tessier
Journal:  Mol Pharm       Date:  2020-06-11       Impact factor: 4.939

Review 2.  Selecting and engineering monoclonal antibodies with drug-like specificity.

Authors:  Charles G Starr; Peter M Tessier
Journal:  Curr Opin Biotechnol       Date:  2019-02-26       Impact factor: 9.740

Review 3.  Protein aggregation: in silico algorithms and applications.

Authors:  R Prabakaran; Puneet Rawat; A Mary Thangakani; Sandeep Kumar; M Michael Gromiha
Journal:  Biophys Rev       Date:  2021-01-17

4.  Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

Authors:  Adriana-Michelle Wolf Pérez; Nikolai Lorenzen; Michele Vendruscolo; Pietro Sormanni
Journal:  Methods Mol Biol       Date:  2022

5.  Nature-inspired design and evolution of anti-amyloid antibodies.

Authors:  Mark C Julian; Lilia A Rabia; Alec A Desai; Ammar Arsiwala; Julia E Gerson; Henry L Paulson; Ravi S Kane; Peter M Tessier
Journal:  J Biol Chem       Date:  2019-03-27       Impact factor: 5.486

6.  Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.

Authors:  Priyanka Gupta; Emily K Makowski; Sandeep Kumar; Yulei Zhang; Justin M Scheer; Peter M Tessier
Journal:  Mol Pharm       Date:  2022-02-02       Impact factor: 5.364

7.  Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis.

Authors:  Kathryn E Tiller; Ratul Chowdhury; Tong Li; Seth D Ludwig; Sabyasachi Sen; Costas D Maranas; Peter M Tessier
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

8.  A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells.

Authors:  Zhizhen Chen; Jie Liu; Dafeng Chu; Yaming Shan; Guixing Ma; Hongmin Zhang; Xiaohua Douglas Zhang; Pu Wang; Qiang Chen; Chuxia Deng; Weizao Chen; Dimiter S Dimitrov; Qi Zhao
Journal:  Int J Biol Sci       Date:  2018-05-21       Impact factor: 6.580

Review 9.  Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.

Authors:  André L B Bitencourt; Raquel M Campos; Erika N Cline; William L Klein; Adriano Sebollela
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

Review 10.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.